IntelliCell Announces article by Ray Dirks of RAY DIRKS Research published on CPReports.com
March 15 2012 - 10:50AM
Business Wire
IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) (PINKSHEETS:
SVFC.PK) announces Ray Dirks Research Article published on
www.CPreports.com .
In an update to Ray Dirks November 2011 report on Intellicell
BioSciences Inc., Mr. Dirks discusses the impact of IntelliCell’s
recent equity raise. In addition, he calls IntelliCell’s Stromal
Vascular Fraction Celluar Therapy a game changer in the treatment
of Orthopedic and sport injury inflammatory conditions.
To view report go to: www.CPReports.com or
http://www.cpreports.com/?p=1929
About CPreports.com
www.CPReports.com features Ray Dirks, Gene Marcial and Robert
Goldman. The website and newsletter provide readers and subscribers
fresh, original, and highly informative ideas and market commentary
that they won’t get anywhere else. Content is focused on what is
going on in the stock market and on Wall Street.
About Ray Dirks Research
Ray Dirks came to Wall Street with Goldman, Sachs & Co. in
1963 where he was established as the leading insurance stock
analyst dealing with institutional investors and high -net worth
investors both in the U.S. and internationally. Ray’s research
includes Healthcare Stocks and Special Situations. Ray has written
two books, “The Great Wall Street Scandal” and “Heads You Win,
Tails You Win,” published by McGraw-Hill and Bantam Books
respectively. He continues to provide research to institutions and
individuals.
About IntelliCell BioSciences, Inc.
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using stromal
vascular fraction derived from adult adipose tissue. IntelliCell
intends to initially focus on selling laboratory suites and
licensing its technology to doctors for use in their offices for
their patients. The company is also setting up Centers of
Excellence where doctors can treat their patients. In addition,
IntelliCell BioScience in exploring storing the stromal vascular
fraction in cryostorage for future uses. The company is also
starting FDA IND clinical trials at major medical centers for
clinical indication approval. IntelliCell intends to pursue
expansion to secondary markets and beyond the U.S. through a
combination of company-owned and licensed clinical facilities. For
additional information, visit http://www.intellicellbiosciences.com
or call 212-249-3050.
Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995:
Except for historical information contained herein, the statements
in this news release are forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities
Act of 1995. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause a company's actual
results, performance and achievement in the future to differ
materially from forecasted results, performance, and achievement.
These risks and uncertainties are described in the Company's
periodic filings with the Securities and Exchange Commission. The
Company undertakes no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made
to reflect events or circumstances after the date hereof, or to
reflect the occurrence of unanticipated events or changes in the
Company's plans or expectation.